The global thrombopoietin receptor market is expected to rise at a considerable CAGR during the forecast period (2022-2028). Thrombopoietin is a glycoprotein hormone that regulates platelet formation and is generated by the liver and kidney. Megakaryocytes, the bone marrow cells that produce a large quantity of platelets, are stimulated to produce and differentiate. TPO receptors are found in mature megakaryocytes and platelets, immature cells of all lineages, CD34+ cells, and pluripotent stem cells, among other hematopoietic cells. They have an impact on all elements of platelet production, from hematopoietic stem cell (HSC) self-renewal and expansion to stimulation of megakaryocyte progenitor cell proliferation and support for the maturation of these cells into platelet-producing cells. The principal physiological regulator of platelet formation is a thrombopoietin (TPO). TPO stimulates megakaryocyte proliferation and platelet formation by binding to the TPO receptor and activating the JAK and STAT pathways. Rising Prevalence of Immune Thrombocytopenia Purpura (ITP) is the major factor that is driving the market growth. High cost of the treatment is the biggest concern that is limiting the market growth. Various government organizations and private firms are collaborating to regulate the drug prices and assist the patients by giving them financial support. This is expected to create scope for the market growth.
Impact of COVID-19 on Global Thrombopoietin Receptor Market.
The Covid-19 has raised the thrombopoietin receptor market. During the infection, all patients had a higher-than-average platelet count, with the platelet count on its peak. As a result, therapeutic adjustments were required. Chronic ITP patients on TPO-RAs with COVID-19 require careful platelet count monitoring and therapeutic control. These factors raised the demand for thrombopoietin receptors hence rises the growth of the thrombopoietin receptor market globally.
Segmental Outlook
The global thrombopoietin receptor market is segmented based on type and application. Based on type, the market is segmented into Eltrombopag Olamine, GSK-2285921, Romiplostim, STST-4, Others. Based on application the market is segmented into Clinic, Hospital, Others.
**The above-mentioned segments can be customized as per the requirements.
Global Thrombopoietin Receptor Market Share by Type, 2021(%)
Eltrombopag Olamine Segment is holding a Prominent Share in the Global Thrombopoietin Receptor market.
Based on type, Eltrombopag Olamine has seen an increase in market share. Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP). Eltrombopag's iron-chelating action inhibits leukemic cell proliferation in vitro and has a TPO-independent effect on activating stem cells and MK precursors in vivo. Eltrombopag had been approved in 2012, for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. WHO estimated that in 2019, approximately 290 000 people died from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer). Globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year. With increase in Hepatitis C prevalence, the demand for Eltrombopag Olamine Thrombopoietin Receptor is increasing.
Regional Outlooks
The global thrombopoietin receptor market is further segmented based on geography Including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). The market in Asia Pacific is expected to record the highest CAGR over the forecast period owing to increasing economic growth and rising awareness of the rare blood disorders among people in the region.
**The market can be analyzed for a particular region or country level as per the requirement.
Global Thrombopoietin Receptor Market Growth, by Region 2022-2028
North America is Expected to Dominate the Global Thrombopoietin Receptor Market.
Geographically, North America region has dominated the global thrombopoietin receptor market in 2021. The market growth is being driven by the high investments in R&D activities, rising awareness of the rare blood disorders, and advanced healthcare facilities due to which the treatment of ITP is easily available in region’s major economies. In addition, new FDA approvals to drug developed by pharmaceutical companies in the region is further driving the market growth.
Market Players Outlook
The major companies serving the global thrombopoietin receptor market include Novartis International AG, Amgen Inc., GlaxoSmithKline plc, 3SBio, Inc., AkaRx, Inc., and others. To enhance their market share, industry participants are employing a number of critical techniques. For example, Intas Pharmaceuticals Ltd. achieved a major step toward making chronic immune thrombocytopenia therapy more accessible in July 2019. Romiplostim was first introduced in India under the name Romy.
The Report Covers
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Thrombopoietin Receptor Market
• Recovery Scenario of Global Thrombopoietin Receptor Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Novartis International AG
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Amgen Inc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. GlaxoSmithKline plc
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. Swot Analysis
3.3.4. Recent Developments
3.4. AstraZeneca PLC
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Takeda Pharmaceutical Company Ltd.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Thrombopoietin Receptor Market by Type
4.1.1. Eltrombopag Olamine
4.1.2. GSK-2285921
4.1.3. Romiplostim
4.1.4. STST-4
4.1.5. Others
4.2. Global Thrombopoietin Receptor Market by END-USER
4.2.1. Clinic
4.2.2. Hospital
4.2.5. Others
5. Regional Analysis
5.1. North America
5.1.1 United States
5.1.2 Canada
5.2. Europe
5.2.1.UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
5.5. Intas Pharmaceuticals Ltd.
5.6. Rigel Pharmaceuticals, Inc.
5.7. Shionogi & Co., Ltd.
5.8. STATegics Inc.
5.9. AkaRx Inc
5.10. 3SBio Inc
1. GLOBAL THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL ELTROMBOPAG OLAMINE THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL GSK-2285921 THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL ROMIPLOSTIM THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL STST-4 THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL OTHER THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028($ MILLION)
8. GLOBAL THROMBOPOIETIN RECEPTOR MARKET IN CLINIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
9. GLOBAL THROMBOPOIETIN RECEPTOR MARKET IN HOSPITAL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
10. GLOBAL THROMBOPOIETIN RECEPTOR MARKET IN OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
11. GLOBAL THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028($ MILLION)
12. NORTH AMERICAN THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
14. NORTH AMERICAN THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
15. EUROPEAN THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. EUROPEAN THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028($ MILLION)
17. EUROPEAN THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
21. REST OF THE WORLD THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD THROMBOPOIETIN RECEPTOR MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL THROMBOPOIETIN RECEPTOR MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL THROMBOPOIETIN RECEPTOR MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL THROMBOPOIETIN RECEPTOR MARKET, 2021-2028 (%)
4. GLOBAL THROMBOPOIETIN RECEPTOR MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL ELTROMBOPAG OLAMINE THROMBOPOIETIN RECEPTOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL GSK-2285921 THROMBOPOIETIN RECEPTOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL ROMIPLOSTIM THROMBOPOIETIN RECEPTOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL STST-4 THROMBOPOIETIN RECEPTOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL OTHER THROMBOPOIETIN RECEPTOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL THROMBOPOIETIN RECEPTOR MARKET SHARE BY END-USER, 2021 VS 2028 (%)
11. GLOBAL THROMBOPOIETIN RECEPTOR MARKET IN CLINIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL THROMBOPOIETIN RECEPTOR MARKET IN HOSPITAL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL THROMBOPOIETIN RECEPTOR MARKET IN OTHER END-USER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL THROMBOPOIETIN RECEPTOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. US THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)
17. UK THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)
26. SOUTH KOREA THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD THROMBOPOIETIN RECEPTOR MARKET SIZE, 2021-2028 ($ MILLION)